Evercore ISI initiated coverage on shares of Bruker (NASDAQ:BRKR) in a research note published on Wednesday. The firm issued an in-line rating and a $36.00 price objective on the medical research company’s stock.

BRKR has been the subject of a number of other reports. JPMorgan Chase & Co. upgraded shares of Bruker from an underweight rating to a neutral rating and set a $28.00 price objective for the company in a research note on Friday, November 3rd. Citigroup raised their price target on shares of Bruker from $29.00 to $34.00 and gave the company a neutral rating in a report on Friday, November 3rd. Goldman Sachs Group reissued a sell rating and issued a $24.00 price target on shares of Bruker in a report on Tuesday, September 26th. Bank of America raised shares of Bruker from an underperform rating to a neutral rating and set a $34.00 price target for the company in a report on Friday, November 3rd. Finally, Zacks Investment Research raised shares of Bruker from a hold rating to a buy rating and set a $37.00 price target for the company in a report on Wednesday, November 8th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of Hold and an average target price of $31.58.

Bruker (NASDAQ BRKR) traded up $0.18 during trading on Wednesday, reaching $34.99. 552,300 shares of the company were exchanged, compared to its average volume of 433,800. Bruker has a fifty-two week low of $21.68 and a fifty-two week high of $36.53. The stock has a market cap of $5,370.02, a price-to-earnings ratio of 37.22, a price-to-earnings-growth ratio of 2.60 and a beta of 1.12. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.60 and a quick ratio of 1.60.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Thursday, November 2nd. The medical research company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.02. Bruker had a net margin of 8.85% and a return on equity of 25.83%. The business had revenue of $435.60 million during the quarter, compared to analyst estimates of $415.45 million. During the same period in the previous year, the business earned $0.32 EPS. Bruker’s revenue was up 10.6% compared to the same quarter last year. equities research analysts anticipate that Bruker will post 1.19 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Friday, December 22nd. Shareholders of record on Monday, December 4th were issued a $0.04 dividend. This represents a $0.16 annualized dividend and a yield of 0.46%. The ex-dividend date of this dividend was Friday, December 1st. Bruker’s payout ratio is 17.02%.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Acrospire Investment Management LLC lifted its holdings in shares of Bruker by 496.1% during the 2nd quarter. Acrospire Investment Management LLC now owns 3,827 shares of the medical research company’s stock worth $110,000 after acquiring an additional 3,185 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Bruker during the 2nd quarter worth $111,000. Zions Bancorporation bought a new stake in shares of Bruker during the 3rd quarter worth $119,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Bruker by 11.3% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,599 shares of the medical research company’s stock worth $133,000 after acquiring an additional 467 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Bruker by 7.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 5,003 shares of the medical research company’s stock worth $144,000 after acquiring an additional 331 shares during the last quarter. 65.60% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Bruker (BRKR) Receives New Coverage from Analysts at Evercore ISI” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2018/01/04/bruker-brkr-receives-new-coverage-from-analysts-at-evercore-isi.html.

Bruker Company Profile

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Analyst Recommendations for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.